Keyword: Zydelig

The first dual PI3K-delta/gamma inhibitor will go up against Gilead's Zydelig, the first PI3K inhibitor, and Bayer’s Aliqopa.

Gilead cancer drug Zydelig--flagged earlier this year after serious adverse events cropped up in studies--can stay on the market with some new recommendations, European regulators have concluded.